We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.75 | 29.85 | 29.89 | 65 | 13:43:11 |
From May 2019 to May 2024
By Olivia Bugault
Roche Holding AG (ROg.EB) said Tuesday that it submitted a supplemental biologics license application to the U.S. Food and Drug Administration for its breast-cancer medicine Kadcyla.
Kadcyla was granted breakthrough therapy designation, which is assigned to drugs designed to treat serious or life-threatening diseases, the Swiss pharmaceutical giant said.
Sandra Horning, Roche's chief medical officer and head of global product development, said Roche is working "closely with the FDA to bring Kadcyla to people with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy as early as possible."
Write to Olivia Bugault at olivia.bugault@dowjones.com
(END) Dow Jones Newswires
February 05, 2019 01:41 ET (06:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
